IBDX^® plus – Glycominds discovered the novel biomarkers Anti-L and Anti-C and is adding these to the existing IBDX^® panel of gASCA, ACCA, ALCA and AMCA. Several retrospective studies and one prospective study have shown that patients that tested positive for IBDX^® plus have higher risk for disease complications and the need for abdominal surgery within 12 months. The IBDX^® plus test will be an improvement to the current IBDX^® panel by identifying additional Crohn’s Disease patients likely to have severe and complicated disease and/or require surgery.

Pediatric Crohn's disease population
Glycominds is participating in the Growth, Relapse, and Outcomes with Therapy (GROWTH) a prospective multi-center study geared to identify predictive clinical and therapeutic parameters in pediatric Crohn’s Disease patients.

Glycominds' goal is to validate that the IBDX^® plus test of anti-glycan antibodies to be utilized for the prognosis of disease activity, and earlier time to relapse, in a pediatric Crohn's disease population. The GROWTH study will enroll three hundred (300) newly diagnosed, untreated pediatric patients with a diagnosis of Crohn's disease. Patients will be followed over a period of two years by a team of pediatric gastroenterologists that represent several IBD centers belonging to the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN).